Scholars Central

Conference abstractPublished 29 Oct 2012

Future therapies for Hepatitis C disease: Ribavarin mono phosphate- inhibitor for protease enzyme

Authors: Sandeep Raja Dangeti

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Protease enzyme is responsible for hydrolysis of proteins. In HCV, during replicative cycle it will help in hydrolysis of proteins so formed. In this work we found the active sites of protease which are acting in hydrolysis and found 10 different drugs available in market, which inhibit the activity of protein. These molecules were docked with the protease enzyme and best interactions were found. The best molecule is Ribavarin and similar molecules for this molecule were collected from DRUG BANK. These molecules were docked the specific site where Ribavarin acted over the protease. Ribavarin mono phosphate is found to be best docked and it is found to be hydrophobic with log P value 6.99. The molecule is found to be new alternative which can inhibit the activity of protease enzyme.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sandeep Raja Dangeti”